Literature DB >> 14999803

Postoperative complications after chemoradiation for advanced head and neck cancer.

Eva Proctor1, K Thomas Robbins, Francisco Vieira, Catherine Hanchett, Grant Sommes.   

Abstract

BACKGROUND: To compare the rate of postoperative complications of patients with advanced head and neck cancer treated with the chemoradiation protocol "RADPLAT" with that of a similar cohort of patients treated with primary surgery.
METHODS: We retrospectively analyzed 50 patients treated with RADPLAT and 50 patients treated with primary surgery.
RESULTS: The rates of complications for local wound problems were 54% and 42%, respectively, for the RADPLAT cohort and the primary surgery cohort. However, the rate of local complications for the subset of RADPLAT patients undergoing clean-contaminated surgery was 69% (p =.305). The rates of complications for medical (systemic) problems were 10% and 12%, respectively, for RADPLAT versus primary surgery patients. There was no significant difference in hospitalization time between the groups.
CONCLUSIONS: Among patients with advanced head and neck cancer, surgical complications are high but not significantly different between patients undergoing the chemoradiation protocol "RADPLAT" and those undergoing primary surgery. Copyright 2004 Wiley Periodicals, Inc. Head Neck 26: 272-277, 2004

Entities:  

Mesh:

Year:  2004        PMID: 14999803     DOI: 10.1002/hed.10374

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

1.  Salvage surgery for local recurrence after chemoradiotherapy or radiotherapy in hypopharyngeal cancer patients.

Authors:  Shigenari Taki; Akihiro Homma; Nobuhiko Oridate; Seigo Suzuki; Fumiyuki Suzuki; Tomohiro Sakashita; Satoshi Fukuda
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-05-22       Impact factor: 2.503

Review 2.  The role of neck dissection in squamous cell carcinoma of the head and neck.

Authors:  Marc Hamoir; Sandra Schmitz; Vincent Gregoire
Journal:  Curr Treat Options Oncol       Date:  2014-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.